Adrenal News

Essentialis Inc., announced the start of an extension trial to evaluate long-term effects of a once-daily diazoxide choline controlled-release tablet for treatment of symptoms related to Prader-Willi syndrome, according to a company press release

Hypercortisolemia in Cushing’s syndrome can be controlled with Metopirone therapy, according to recent study findings published in The Journal of Clinical Endocrinology & Metabolism.

In patients undergoing coronary revascularization, a flatter preoperative diurnal cortisol slope appears to be associated with poorer long-term outcomes, according to recent findings.

Measuring 24-hour urinary free cortisol with liquid chromatography-mass spectrometry is the most accurate first-line diagnostic tool for diagnosing Cushing’s syndrome in adults, according to research published in The Journal of Clinical Endocrinology & Metabolism.

The Endocrine Society and the European Society for Endocrinology issued a new clinical practice guideline for managing Cushing’s syndrome, recommending tumor removal as a first-line treatment, according to research in The Journal of Clinical Endocrinology & Metabolism.

The FDA granted breakthrough therapy designation to Ultratrace iobenguane I-131 for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma, according to a press release from the drug’s manufacturer.

Endocrine Today has compiled a list of the top five adrenal stories posted in the last month.

Women with overweight and class I obesity appear to have the lowest cortisol levels, while more significant obesity appears to be associated with higher cortisol levels, according to recent findings.

Women with anorexia nervosa have significantly elevated levels of betatrophin, whereas those with morbid obesity have reduced levels of the hormone when compared with normal-weight women, according to research in The Journal of Clinical Endocrinology & Metabolism.

Evidence of Crooke hyaline changes in the pituitary gland points to a higher likelihood of Cushing’s syndrome in adults, with the changes in basophil cells occurring in 75% to 80% of patients with the hormonal disorder, according to research in The Journal of Clinical Endocrinology & Metabolism.